**X-LINKED LYMPHOPROLIFERATIVE DISEASE (XLP)**

**GENES TESTED:** SH2D1A, BIRC4

The diagnosis of X-linked lymphoproliferative syndrome (XLP) should be suspected in males with fulminant Epstein-Barr virus (EBV) induced mononucleosis which may be accompanied by hemophagocytosis. Affected males who survive the initial EBV infection develop a variable hypogammaglobulinemia and have a high risk of developing malignant lymphoma or other lymphoproliferative disease. Symptoms of XLP develop in some individuals without evidence of EBV infection.

Mutations in SH2D1A account for at least 60% of cases of X-linked lymphoproliferative disease (XLP1). Affected males who survive the initial EBV infection develop a variable hypogammaglobulinemia and have a high risk of developing malignant lymphoma or other lymphoproliferative disease. Symptoms of XLP develop in some individuals without evidence of EBV infection. SH2D1A maps to Xq24-26 and encodes a 128 amino acid protein known as SAP (SLAM associated protein) which is involved in lymphocyte activation signaling. The gene consists of four exons and three introns. Mutations involving all four exons have been identified. Large deletions account for approximately 25% of identified mutations in SH2D1A. NK cell function and SAP protein expression by flow cytometry are typically abnormal in individuals with mutations in SH2D1A.

**BIRC4**, the gene responsible for XLP2, maps to Xq25, and is identified in a minority of males with XLP. More commonly, we have identified BIRC4 mutations in young males with hemophagocytic syndrome. BIRC4, consisting of six exons and five introns, encodes a 497 amino acid protein known as XIAP (X-linked inhibitor of apoptosis). Large deletions account for about one-third of mutations in BIRC4. XIAP protein expression by flow cytometry is typically abnormal in individuals with mutations in BIRC4. Splenomegaly was noted in the few patients reported to date with mutations in BIRC4 while splenomegaly is not a typical feature of XLP secondary to mutations in SH2D1A. Unlike patients with SH2D1A mutations, progression to lymphoma has not been reported to date in male patients with BIRC4 mutations.

Other cause of lymphoproliferation and/or hemophagocytic syndrome, both genetic and nongenetic, should also be considered in patients presenting with lymphoproliferative disease.

**INDICATIONS:**

- Diagnosis in a symptomatic individual
- Presymptomatic diagnosis in an at-risk individual
- Carrier identification in females with a family history
- Prenatal diagnosis of an at-risk fetus, after identification of a mutation in a proband (by prior arrangement only)
SPECIMEN: At least 5 mLs whole blood in lavender top (EDTA) tube. Label tube with patient’s name, birth date, and date of collection. Cytobrushes are required for analysis in patients who have undergone transplantation and may facilitate DNA isolation in patients undergoing chemotherapy or in individuals with leukopenia. Please call for a free cytobrush collection kit.

METHODOLOGY: PCR-based sequencing of entire coding region and intron/exon boundaries of the SH2D1A and BIRC4 genes. Testing may be ordered sequentially or tandemly. SAP and XIAP protein expression by flow cytometry may be helpful in determining the most cost-effective order of tests. Please contact the Diagnostic Immunology Laboratory at 513-636-4769 for more information about SAP and XIAP testing.

SENSITIVITY & SPECIFICITY: The sensitivity of PCR-based sequence analysis is over 99% for the detection of nucleotide base changes, small deletions, and insertions in the regions analyzed. Mutations in regulatory regions or other untranslated regions are not detected by this test. Multiple exon deletions, large insertions and genetic recombinational events will not be identified in females using this test methodology. Large deletions account for at least 25% of mutations in SH2D1A and BIRC4 and are not by this test methodology in female carriers.

TURN-AROUND TIME: 30 days

COST: Please call 1-866-450-4198 for current pricing or with any billing questions.

CPT CODES: 

<table>
<thead>
<tr>
<th>Gene</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>SH2D1A</td>
<td>81404</td>
</tr>
<tr>
<td>BIRC4</td>
<td>81479</td>
</tr>
<tr>
<td>Family specific study</td>
<td>81403</td>
</tr>
</tbody>
</table>

RESULTS: Results will be reported to the referring physician or health care provider as specified on the requisition form.

Updated 10/15